全盆腔放疗联合三维适形放疗配合口服希罗达治疗老年晚期直肠癌  

Radiotherapy of the whole Pelvic and 3DCRT combined with Xeloda for elderly patients with rectal cancer

作　　者：王力军[1] 冯济龙[1] 

机构地区：[1]沈阳市第五人民医院,辽宁沈阳110023

出　　处：《中国民康医学》2011年第21期2624-2626,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:探讨全盆腔放疗联合三维适形放疗(3DCRT)配合口服希罗达(卡培他滨)治疗术后区域复发及局部晚期的老年直肠癌的临床疗效。方法:52例术后区域复发及局部晚期老年直肠癌患者均给予全盆腔放疗联合3DCRT,其中同期口服希罗达组(研究组)30例,单纯放疗组(对照组)22例。结果:研究组和对照组症状缓解率分别为96.7%和72.7%(P<0.05);有效率(CR+PR)分别为86.7%和59.1%(P<0.05);2年生存率分别为56.7%、40.9%(P>0.05);2年远处转移率分别为76.7%、77.3%(P>0.05);两组在不良反应方面未见明显差异(P>0.05)。结论:全盆腔放疗联合三维适形放疗结合口服希罗达治疗术后区域复发及局部晚期的老年直肠癌可提高近期疗效,改善生存质量,且不良反应可以耐受。Objective：To study the outcome of recurrent or locally advanced elderly patients with rectal cancer treated by radiotherapy of the whole pelvic and three dimensional-conformal radiotherapy（3DCRT） combined with Xeloda.Methods：Fifty-two patients with recurrent or locally advanced elderly patients with rectal cancer were treated by radiotherapy,plus Xeloda（tested group,30 patients） and radiotherapy alone（control group,22 patients）.Results： The symptoms-alleviation rates were 96.7% and 72.7%（P0.05）,with efficient（CR＋PR） rates of 86.7% and 59.1%（P0.05）,in the tested and control group.The 2-year survival rates were 56.7% and 40.9% respectively（P0.05）,and 2-year distant metastasis rates were 76.7% and 77.3%（P0.05）,in the tested and control group.The side effects were similar between the two groups（P0.05）.Conclusions： Recurrent or locally advanced elderly patients with rectal cancer treated by radiotherapy of the whole pelvic and 3DCRT combined with Xeloda may improve the recently effects and the quality of life,and its toxicity is tolerable.

关 键 词：直肠癌 三维适形放疗 希罗达 

分 类 号：R735.37[医药卫生—肿瘤]